Croda Pharma has introduced a critical range of new bioprocessing detergents optimised for viral inactivation and cell lysis. The company’s new product range, Virodex™, offers an answer to the key market need for replacing the popular, but now banned, bioprocessing detergent, Triton™ X-100.
Read moreDyadic & bYoRNA announced that they entered into a development and commercialization agreement to work on disruptive bioproduction technologies that will help exploit the therapeutic potential of mRNA.
Read moreArthritis4Cure is developing research and development activities, with a particular focus on biomedicines, cell therapies and other therapies for autoimmune diseases.
Read moreSoft Cell Therapeutics offers services based on a disruptive production process that increases the yield and quality of sensitive cells.
Read moreAIS Biotech's ambition is to develop a new class of anti-infective biotherapeutics.
Read moreThis is a unique website which will require a more modern browser to work!
Please upgrade today!
